Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.

Science advances·2026

Same author

Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109.

Cancer treatment and research communications·2026

Same author

Whole genome sequencing of locally advanced and metastatic breast carcinoma unravels relevant molecular signatures and novel events.

Pathology, research and practice·2026

Same author

Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.

Cancer research communications·2026

Same author

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Search research articles

Related Experiment Video

Updated: May 9, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Systemic therapy for small cell lung cancer.

Benjamin Levy¹, Ashish Saxena, Bryan J Schneider

¹Division of Hematology/Oncology, Department of Internal Medicine, Beth Israel Comprehensive Cancer Center, New York, New York, USA.

Journal of the National Comprehensive Cancer Network : JNCCN

|July 13, 2013

Summary

This summary is machine-generated.

Small cell lung cancer remains aggressive, with limited treatment advances. Current standard care involves platinum doublets, but new targeted therapies show promise for this challenging disease.

Related Experiment Videos

Last Updated: May 9, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Oncology
Medical Oncology
Cancer Research

Background:

Small cell lung cancer (SCLC) is a highly aggressive malignancy known for its genetic complexity and rapid progression.
Current treatment for extensive-stage SCLC largely relies on platinum-based chemotherapy doublets, with cisplatin/etoposide as the long-standing standard of care for over three decades.
Despite decades of research, significant therapeutic breakthroughs for advanced SCLC remain limited, highlighting an unmet clinical need.

Purpose of the Study:

To review the current landscape of chemotherapy for extensive-stage small cell lung cancer.
To discuss the efficacy and toxicity profiles of established and alternative chemotherapy regimens.
To explore emerging strategies and potential targeted therapies based on recent genetic discoveries.

Main Methods:

Literature review of clinical trials and treatment guidelines for small cell lung cancer.
Analysis of chemotherapy regimens, including platinum doublets and second-line options.
Examination of research into novel therapeutic targets and genetic alterations in SCLC.

Main Results:

Cisplatin/etoposide, cisplatin/irinotecan, and carboplatin/etoposide are standard first-line options, each with distinct toxicity profiles.
Maintenance chemotherapy, 3-drug combinations, and high-dose chemotherapy have not improved survival compared to standard platinum doublets.
Topotecan is the sole FDA-approved agent for second-line treatment, with other options available for relapsed or progressive disease.

Conclusions:

Platinum-based doublets remain the cornerstone of first-line treatment for extensive-stage SCLC, necessitating careful consideration of toxicity.
Despite extensive research, survival improvements beyond standard chemotherapy have been minimal.
Emerging research into actionable genetic alterations offers hope for developing more effective, targeted therapies for SCLC in the future.